Conceptos y tendencias actuales | 22 JUN 15

Síndrome de Cushing subclínico

Se analizan los criterios diagnósticos y las implicancias clínicas del síndrome de Cushing subclínico, como así el tratamiento quirúrgico. Hasta la fecha, el estándar de oro para el manejo síndrome de Cushing subclínico es la adrenalectomía laparoscópica.
3
20
Autor/a: Cita: George N. Zografos, Iraklis Perysinakis,1 Evangeline Vassilatou Fuente: HORMONES 2014, 13(3):323-337 Subclinical Cushing’s syndrome: Current concepts and trends
INDICE:  1.  | 2. Referencias
Referencias

1. Commons RR, Callaway CP, 1948 Adenomas of the adrenal cortex. Arch Intern Med (Chic) 81: 37-41.
2. Hedeland H, Ostberg G, Hokfelt B, 1968 On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand184: 211-214.
3. Korobkin M, White EA, Kressel HY, Moss AA, Montagne JP, 1979 Computed tomography in the diagnosis of adrenal disease. AJR Am J Roentgenol 132: 231-238.
4. Nieman LK, 2010 Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 95: 4106-4113.
5. Terzolo M, Pia A, Reimondo G, 2012 Subclinical Cushing’s syndrome: definition and management. Clin Endocrinol (Oxf) 76: 12-18.
6. Z eiger MA, Siegelman SS, Hamrahian AH, 2011 Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab 96: 2004-2015.
7. Beierwaltes WH, Sturman MF, Ryo U, Ice RD, 1974 Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med 15: 246-251.
8. G ross MD, Wilton GP, Shapiro B, et al, 1987 Functional and scintigraphic evaluation of the silent adrenal mass. J Nucl Med 28: 1401-1407.
9. Huiras CM, Pehling GB, Caplan RH, 1989 Adrenal insufficiency after operative removal of apparently nonfunctioning adrenal adenomas. JAMA 261: 894-898.
10. Hensen J, Buhl M, Bahr V, Oelkers W, 1990 Endocrine activity of the “silent” adrenocortical adenoma is uncovered by response to corticotropin-releasing hormone. Klin Wochenschr 68: 608-614.
11. Suzuki T, Sasano H, Sawai T, et al, 1992 Small adrenocortical tumors without apparent clinical endocrine abnormalities. Immunolocalization of steroidogenic enzymes. Pathol Res Pract 188: 883-889.
12. R acz K, Pinet F, Marton T, Szende B, Glaz E, Corvol P, 1993 Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and “nonfunctioning” adrenal adenomas. J Clin Endocrinol Metab 77: 677-682.
13. Charbonnel B, Chatal JF, Ozanne P, 1981 Does the corticoadrenal adenoma with “pre-Cushing’s syndrome” exist? J Nucl Med 22: 1059-1061.
14. R eincke M, Nieke J, Krestin GP, Saeger W, Allolio B, Winkelmann W, 1992 Preclinical Cushing’s syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab 75: 826-832.
15. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M, 1999 Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84: 520-526.
16. Bulow B, Jansson S, Juhlin C, et al, 2006 Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol 154: 419-423.
17. Vassilatou E, Vryonidou A, Michalopoulou S, et al, 2009 Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf) 70: 674-679.
18. G rumbach MM, Biller BM, Braunstein GD, et al, 2003 Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 138: 424-429.
19. M antero F, Terzolo M, Arnaldi G, et al, 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85: 637-644.
20. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B, 1995 Incidentally discovered adrenal masses. Endocr Rev 16: 460-484.
21. Terzolo M, Osella G, Ali A, et al, 1998 Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 48: 89-97.
22. Fagour C, Bardet S, Rohmer V, et al, 2009 Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. Eur J Endocrinol 160: 257-264.
23. O lsen H, Nordenstrom E, Bergenfelz A, Nyman U, Valdemarsson S, Palmqvist E, 2012 Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42: 164-173.
24. G rossrubatscher E, Vignati F, Possa M, Lohi P, 2001 The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation. J Endocrinol Invest 24: 846-855.
25. M orelli V, Reimondo G, Giordano R, et al, 2014 Longterm follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99: 827-834.
26. Vassiliadi DA, Ntali G, Vicha E, Tsagarakis S, 2011 High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol (Oxf) 74: 438-444.
27. Androulakis II, Kaltsas GA, Markou A, et al, 2011 The functional status of incidentally discovered bilateral adrenal lesions. Clin Endocrinol (Oxf) 75: 44-49.
28. M orelli V, Palmieri S, Salcuni AS, et al, 2013 Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics. Eur J Endocrinol 168: 235-241.
29. Arnaldi G, Boscaro M, 2012 Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 26: 405-419.
30. Nieman LK, Biller BM, Findling JW, et al, 2008 The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526-1540.
31. Barzon L, Scaroni C, Sonino N, et al, 1998 Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 83: 55-62.
32. Valli N, Catargi B, Ronci N, et al, 2001 Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol 144:401-408.
33. R ossi R, Tauchmanova L, Luciano A, et al, 2000 Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85: 1440-1448.
34. Tauchmanova L, Rossi R, Biondi B, et al, 2002 Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87: 4872-4878.
35. Terzolo M, Pia A, Ali A, et al, 2002 Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87: 998-1003.
36. Tsagarakis S, Kokkoris P, Roboti C, et al, 1998 The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 48: 627-633.
37. Piaditis GP, Kaltsas GA, Androulakis, II, et al, 2009 High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 71: 772-778.
38. Kaltsas G, Chrisoulidou A, Piaditis G, Kassi E, Chrousos G, 2012 Current status and controversies in adrenal incidentalomas. Trends Endocrinol Metab 23: 602-609.
39. Stewart PM, 2010 Is subclinical Cushing’s syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab 95: 2618-2620.
40. Z eiger MA, Thompson GB, Duh QY, et al, 2009 The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15 Suppl 1: 1-20.
41. Palmieri S, Morelli V, Polledri E, et al, 2013 The role of salivary cortisol measured by liquid chromatographytandem mass spectrometry in the diagnosis of subclinical hypercortisolism. Eur J Endocrinol 168: 289-296.
42. Tabarin A, Bardet S, Bertherat J, et al, 2008 Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol (Paris) 69: 487-500.
43. Terzolo M, Stigliano A, Chiodini I, et al, 2011 AME position statement on adrenal incidentaloma. Eur J Endocrinol 164: 851-870.
44. M ansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR, 2004 The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25: 309-340.
45. Hamrahian AH, Ioachimescu AG, Remer EM, et al, 2005 Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 90: 871-877.
46. Lee MJ, Hahn PF, Papanicolaou N, et al, 1991 Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis.
Radiology 179: 415-418.
47. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F, 1998 CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170: 747-752.
48. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR, 2000 Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrastenhanced CT. Radiology 217: 798-802.
49. Caoili EM, Korobkin M, Francis IR, et al, 2002 Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222: 629-633.
50. Szolar DH, Kammerhuber FH, 1998 Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. Radiology 207: 369-375.
51. Blake MA, Kalra MK, Sweeney AT, et al, 2006 Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 238: 578-585.
52. Low G, Dhliwayo H, Lomas DJ, 2012 Adrenal neoplasms. Clin Radiol 67: 988-1000. 53. Lumachi F, Marchesi P, Miotto D, Motta R, 2011 CT and
MR imaging of the adrenal glands in cortisol-secreting tumors. Anticancer Res 31: 2923-2926.
54. Di Dalmazi G, Vicennati V, Rinaldi E, et al, 2012 Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol 166:669-677.
55. Hadjidakis D, Tsagarakis S, Roboti C, et al, 2003 Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol (Oxf) 58: 72-77.
56. Chiodini I, Morelli V, Masserini B, et al, 2009 Bone Subclinical cushing’s syndrome: Current concepts and trends 335 mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 94: 3207-3214.
57. M idorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T, 2001 The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54: 797-804.
58. E rbil Y, Ozbey N, Barbaros U, Unalp HR, Salmaslioglu A, Ozarmagan S, 2009 Cardiovascular risk in patient with nonfunctional adrenal incidentaloma: myth or reality? World J Surg 33: 2099-2105.
59. R eincke M, Fassnacht M, Vath S, Mora P, Allolio B, 1996 Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22: 757-761.
60. O sella G, Reimondo G, Peretti P, et al, 2001 The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J Clin Endocrinol Metab 86: 604-607.
61. Yener S, Ertilav S, Secil M, et al, 2012 Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas. Med Princ Pract 21: 429-434.
62. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E, 2009 Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 249: 388-391.
63. Perysinakis I, Marakaki C, Avlonitis S, et al, 2013 Laparoscopic adrenalectomy in patients with subclinical Cushing syndrome. Surg Endosc 27: 2145-2148. 64. Bernini G, Moretti A, Iacconi P, et al, 2003 Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 148: 213-219.
65. Chiodini I, Morelli V, Salcuni AS, et al, 2010 Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95: 2736-2745.
66. E ller-Vainicher C, Morelli V, Salcuni AS, et al, 2010 Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery? Eur J Endocrinol 162: 91-99.
67. Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K, 2008 Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr J 55: 737-745.
68. M itchell IC, Auchus RJ, Juneja K, et al, 2007 “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142: 900-905.
69. M orelli V, Masserini B, Salcuni AS, et al, 2010 Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 73: 161-166.
70. O ki K, Yamane K, Nakanishi S, Shiwa T, Kohno N, 2012 Influence of adrenal subclinical hypercortisolism on hypertension in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 120: 244-247.
71. Terzolo M, Bovio S, Pia A, et al, 2005 Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol 153: 307-315.
72. Iacobone M, Citton M, Viel G, et al, 2012 Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing’s syndrome. Surgery 152: 991-997.
73. Akaza I, Yoshimoto T, Iwashima F, et al, 2011 Clinical outcome of subclinical Cushing’s syndrome after surgical and conservative treatment. Hypertens Res 34: 1111-1115.
74. Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M, 2009 Glucocorticoid response elements and 11 betahydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res 81: 140-147.
75. Hamm LL, Hering-Smith KS, 2010 Pivotal role of the kidney in hypertens on. Am J Med Sci 340: 30-32.
76. R ossi GP, Andreis PG, Colonna S, et al, 2002 Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab 87: 322-328.
77. Xiao D, Huang X, Bae S, Ducsay CA, Zhang L, 2002 Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy. Am J Physiol Heart Circ Physiol 283: H238-246.
78. M artins LC, Conceicao FL, Muxfeldt ES, Salles GF, 2012 Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens 30: 967-973.
79. Lambillotte C, Gilon P, Henquin JC, 1997 Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99: 414-423.
80. Plat L, Byrne MM, Sturis J, et al, 1996 Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol 270: E36-42.
81. Vegiopoulos A, Herzig S, 2007 Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275: 43-61.
82. Van Raalte DH, Ouwens DM, Diamant M, 2009 Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39: 81-93.
83. G iordano R, Guaraldi F, Berardelli R, et al, 2012 Glucose metabolism in patients with subclinical Cushing’s syndrome. Endocrine 41: 415-423.
84. M urakami H, Nigawara T, Sakihara S, et al, 2010 The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical
Cushing’s disease. Endocr J 57: 267-272.
85. Ivovic M, Marina LV, Vujovic S, et al, 2013 Nondiabetic patients with either subclinical Cushing’s or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: clinical implications. Metabolism 62: 786-792.
86. Androulakis, II, Kaltsas G, Piaditis G, Grossman AB, 2011 The clinical significance of adrenal incidentalomas. Eur J Clin Invest 41: 552-560.
87. Caetano MS, Silva Rdo C, Kater CE, 2007 Increased diagnostic probability of subclinical Cushing’s syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol 51: 1118-1127.
88. G arrapa GG , Pantanetti P, Arnaldi G, Mantero F, Faloia E, 2001 Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab 86: 5301-5306.
89. M orelli V, Eller-Vainicher C, Salcuni AS, et al, 2011 Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 26: 1816-1821.
90. Chiodini I, Torlontano M, Carnevale V, et al, 2001 Bone loss rate in adrenal incidentalomas: a longitudinal study. J Clin Endocrinol Metab 86: 5337-5341.
91. Chiodini I, Viti R, Coletti F, et al, 2009 Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol (Oxf) 70: 208-213.
92. Swiatkowska-Stodulska R, Kaniuka-Jakubowska S, Wisniewski P, et al, 2012 Homocysteine and alpha-1 antitrypsin concentration in patients with subclinical hypercortisolemia. Adv Med Sci 57: 302-307.
93. Csernansky JG, Dong H, Fagan AM, et al, 2006 Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry 163: 2164-2169.
94. G uldiken S, Guldiken B, 2008 Subclinical Cushing’s syndrome is a potential cause of metabolic dementia and rapidly progressive Alzheimer-type dementia. Med Hypotheses 71: 703-705.
95. E mral R, Uysal AR, Asik M, et al, 2003 Prevalence of subclinical Cushing’s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 50: 399-408.
96. Terzolo M, Osella G, Ali A, et al, 1996 Different patterns of steroid secretion in patients with adrenal incidentaloma. J Clin Endocrinol Metab 81: 740-744.
97. E rbil Y, Ademoglu E, Ozbey N, et al, 2006 Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 30: 1665-1671.
98. Shen WT, Lee J, Kebebew E, Clark OH, Duh QY, 2006 Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg 141:771-774.
99. O gilvie JB, Duh QY, 2005 New approaches to the minimally invasive treatment of adrenal lesions. Cancer J 11: 64-72.
100. Kwok KC, Lo CY, 2003 Applicability and outcome of laparoscopic adrenalectomy. Asian J Surg 26: 71-75.
101. Bonjer HJ, Sorm V, Berends FJ, et al, 2000 Endoscopic retroperitoneal adrenalectomy: lessons learned from 111 consecutive cases. Ann Surg 232: 796-803.
102. Z ografos GN, Markou A, Ageli C, et al, 2006 Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens) 5: 52-56.
103. Bjornsson B, Birgisson G, Oddsdottir M, 2008 Laparoscopic adrenalectomies: A nationwide single-surgeon experience. Surg Endosc 22: 622-626.
104. Lezoche E, Guerrieri M, Crosta F, et al, 2008 Perioperative results of 214 laparoscopic adrenalectomies by anterior transperitoneal approach. Surg Endosc 22:522-526.
105. E lfenbein DM, Scarborough JE, Speicher PJ, Scheri RP, 2013 Comparison of laparoscopic versus open adrenalectomy: results from American College of Surgeons-National Surgery Quality Improvement Project. J Surg Res 184: 216-220.
106. R amacciato G, Nigri GR, Petrucciani N, et al, 2011 Minimally invasive adrenalectomy: a multicenter comparison of transperitoneal and retroperitoneal approaches. Am Surg 77: 409-416.
107. Alesina PF, Hommeltenberg S, Meier B, et al, 2010 Posterior retroperitoneoscopic adrenalectomy for clinical and subclinical Cushing’s syndrome. World J Surg 34: 1391-1397.
108. Kiriakopoulos A, Economopoulos KP, Poulios E, Linos D, 2011 Impact of posterior retroperitoneoscopic adrenalectomy in a tertiary care center: a paradigm shift. Surg Endosc 25: 3584-3589.
109. Iacobone M, Albiger N, Scaroni C, et al, 2008 The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 32: 882-889.
110. Young WF Jr, du Plessis H, Thompson GB, et al, 2008 The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 32: 856-862.
111. Kawasaki Y, Ishidoya S, Kaiho Y, et al, 2011 Laparoscopic simultaneous bilateral adrenalectomy: assessment of feasibility and potential indications. Int J Urol 18: 762-767.
112. G rubbs EG, Rich TA, Ng C, et al, 2013 Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216: 280-289.
113. He HC, Dai J, Shen ZJ, et al, 2012 Retroperitoneal adrenal-sparing surgery for the treatment of Cushing’s syndrome caused by adrenocortical adenoma: 8-year experience with 87 patients. World J Surg 36: 1182-1188.
114. Diner EK, Franks ME, Behari A, Linehan WM, Walther MM, 2005 Partial adrenalectomy: the National Cancer Institute experience. Urology 66: 19-23.
115. M iyazato M, Ishidoya S, Satoh F, et al, 2011 Surgical outcomes of laparoscopic adrenalectomy for patients with Cushing’s and subclinical Cushing’s syndrome: a single center experience. Int Urol Nephrol 43: 975-981.
116. Yener S, Ertilav S, Secil M, et al, 2010 Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 33: 32-36.
117. Tsvetov G, Shimon I, Benbassat C, 2007 Adrenal incidentaloma: clinical characteristics and comparison between patients with and without extraadrenal malignancy. J Endocrinol Invest 30: 647-652.
118. Anagnostis P, Efstathiadou Z, Polyzos SA, et al, 2010 Long term follow-up of patients with adrenal incidentalomas--a single center experience and review of the literature. Exp Clin Endocrinol Diabetes 118:610-616.
119. Young WF, Jr, 2007 Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356: 601-610. 120. Berland LL, Silverman SG, Gore RM, et al, 2010
Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 7: 754-773.
121. Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S, 2009 Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 161: 513-527.
122. De Leo M, Cozzolino A, Colao A, Pivonello R, 2012 Subclinical Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 26: 497-505.
123. M orioka M, Fujii T, Matsuki T, et al, 2000 Preclinical Cushing’s syndrome: report of seven cases and a review of the literature. Int J Urol 7: 126-132.
124. Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck- Peccoz P, Ambrosi B, 2002 Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 147: 489-494.
125. Barzon L, Fallo F, Sonino N, Boscaro M, 2002 Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 146: 61-66.
126. Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C, Salvetti A, 2005 Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer 92: 1104-1109.
127. G iordano R, Marinazzo E, Berardelli R, et al, 2010 Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol 162: 779-785.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020